Main Cause of Prostate Enlargement (Benign Prostatic Hyperplasia, BPH)

• Dihydrotestosterone (DHT): Testosterone is converted to DHT by the enzyme 5-alpha-reductase within prostatic stromal cells. DHT is a more potent androgen than testosterone and binds androgen receptors, stimulating growth factor release (e.g., FGF, TGF-beta) that drives proliferation of stromal and epithelial cells and inhibits cell death - leading to nodular enlargement over decades.
• Aging: BPH is strongly age-dependent - histologic evidence is present in about 20% of men by age 40, rising to 70% by age 60 and over 90% by age 80-90, though not all develop symptoms.
• Altered estrogen-to-androgen ratio: As men age, relative estrogen levels rise, which may sensitize prostate tissue to the growth-promoting effects of androgens.
• Stromal-epithelial signaling: Growth factors produced in the stroma act on epithelium in a paracrine fashion, a key mechanism in nodule formation.

• Metabolic syndrome, insulin resistance, and obesity are increasingly recognized as associated with BPH pathogenesis through inflammatory and metabolic pathways (PMID: 39488266, 2024 systematic review).
• Chronic prostatic inflammation.
• Genetic/familial predisposition.

Treatment for Age-Related Prostate Enlargement (BPH)

1. Watchful Waiting / Lifestyle Measures

• Reduce evening fluid intake, caffeine, and alcohol
• Timed voiding, avoid decongestants/antihistamines (worsen outlet obstruction)
• Weight loss and management of metabolic syndrome (increasingly linked to BPH progression)

2. Medical Therapy (moderate-severe symptoms)

• Relax prostatic and bladder-neck smooth muscle for rapid symptom relief (days)
• Do not shrink the gland - Katzung's Pharmacology notes doxazosin's class use is "Hypertension - benign prostatic hyperplasia," with first-dose orthostatic hypotension as a key adverse effect.

• Block conversion of testosterone to DHT, shrinking the gland over 6-12 months and reducing long-term risk of retention/surgery
• Best for larger prostates (>30-40 g)
• Per Lippincott's Pharmacology, finasteride's adverse effects include decreased libido, decreased ejaculation, and erectile dysfunction; it must not be handled by pregnant women due to teratogenic risk to a male fetus.

• Superior long-term reduction in symptom progression versus either drug alone, per Campbell-Walsh Urology's trial data on dutasteride/tamsulosin combinations.

• Improve LUTS, useful when erectile dysfunction coexists

3. Minimally Invasive Surgical Therapies (MIST)

• Prostatic urethral lift (UroLift), water vapor thermal therapy (Rezum), prostate artery embolization, Aquablation
• A 2024 systematic review in geriatric patients found these options have favorable safety profiles with fewer sexual side effects than TURP, though efficacy durability varies (PMID: 38656693).

4. Surgical Therapy (moderate-severe symptoms, retention, complications)

• Transurethral resection of prostate (TURP) remains the reference standard
• Laser enucleation (HoLEP), photoselective vaporization (PVP/GreenLight), open/robotic simple prostatectomy for very large glands
• A 2024 network meta-analysis comparing newer surgical interventions found differences in re-intervention rates across techniques, useful for counseling patients on durability of effect (PMID: 38600763).

Other/Adjunct

• Intraprostatic botulinum toxin injection has been studied as a minimally invasive option; a 2024 meta-analysis found some symptom benefit, though evidence quality is mixed and it's not yet standard of care (PMID: 35023701).

Practical approach by severity

Where this changes the plan

• Alpha-blocker + 5-alpha-reductase inhibitor (e.g., tamsulosin + dutasteride) - per Bailey & Love's Short Practice of Surgery, "combination therapy has a better outcome in glands bigger than 35 g," and your gland is more than double that threshold. The 5-ARI component is particularly important here because it actually shrinks glandular tissue and reduces future retention/surgery risk, whereas the alpha-blocker only relaxes smooth muscle for symptom relief.
• Response should be monitored over 6-12 months; if IPSS remains high, retention occurs, or there's recurrent hematuria/UTI/renal impairment, move to intervention.

• Standard TURP becomes technically harder and carries higher bleeding/fluid-absorption (TUR syndrome) risk once glands exceed roughly 80-100 g, because of longer resection time - Campbell-Walsh Urology notes "patients with large prostate volumes (e.g., >80 g) often offer technical challenges to the surgeon... larger prostates tend to fill most of the pelvic cavity making maneuverability more difficult."
• HoLEP (Holmium Laser Enucleation of the Prostate) is generally now the preferred size-independent option even for very large glands. Hinman's Atlas of Urologic Surgery notes it is "particularly advantageous for the treatment of large prostate, providing a minimally invasive alternative to open simple prostatectomy," with outcomes comparable to open surgery but shorter catheterization/hospital stay and less bleeding. Recent literature confirms HoLEP performs well even at very large volumes, though some series suggest slightly higher complexity/complication rates at the extreme end (>150-200 cc) (PMID: 39641120, 37716456).
• Open or robotic-assisted simple prostatectomy remains an option, particularly where laser enucleation expertise isn't available, but carries more blood loss and longer recovery than HoLEP. A 2023 comparative study found HoLEP, open, and robotic simple prostatectomy all achieve good symptom outcomes for large-gland BPH, with HoLEP generally showing shorter hospital stay and less blood loss (PMID: 36586427).
• GreenLight PVP (photoselective vaporization) and bipolar TURP are also feasible at experienced centers but data favor HoLEP for glands this large.
• Prostate artery embolization is an alternative for men who are poor surgical/anesthesia candidates, per Campbell-Walsh, though outcomes are generally less robust than resection/enucleation for symptom control.

Practical takeaway for your situation

1. If LUTS are mild-moderate and no complications (no retention, stones, renal impairment, recurrent bleeding/infection): trial combination alpha-blocker + 5-ARI therapy for 6-12 months.
2. If symptoms are severe, medical therapy fails, or complications are present: HoLEP is the best-supported minimally invasive surgical option for an 80g gland at a center with laser expertise; open/robotic simple prostatectomy is a solid alternative.
3. Age 61 alone is not a barrier to any of these options - fitness for anesthesia and comorbidities matter more than age itself at this stage.

Standard Dosing for BPH Medications

Alpha-blockers (symptom relief - pick one)

5-alpha-reductase inhibitors (shrink the gland - relevant given the 80g size)

Combination product

• Dutasteride 0.5 mg + Tamsulosin 0.4 mg once daily (marketed as a fixed-dose combination, e.g., Jalyn) - this is the combination Bailey & Love notes as superior for glands over 35 g, which fits an 80 g prostate well.

Adjunct (if erectile dysfunction coexists)

• Tadalafil 5 mg once daily (the low-dose daily regimen used for LUTS, distinct from the on-demand ED dose)

Important caveats

• These are standard adult starting/maintenance doses from major pharmacology and urology references, not a personalized prescription.
• The actual dose must be set by the prescribing physician based on renal function, liver function, blood pressure, concurrent medications (especially other antihypertensives, which compound alpha-blocker hypotension), and how the patient tolerates titration.
• Alpha-blockers need dose titration to avoid orthostatic hypotension, especially in a 61-year-old who may be on other BP medications.
• 5-ARIs take 6-12 months to show full effect on gland size and symptoms.
• I have not prescribed or verified this for you personally, this is reference information only. A urologist or physician should confirm the specific regimen and monitor PSA (5-ARIs roughly halve PSA levels, which needs to be accounted for when screening for prostate cancer) and liver/renal function as appropriate.

Why they're not directly linked

What urethral/bladder outlet obstruction actually does

When you might see both elevated together (indirect, not causal)

1. Urosepsis/severe UTI from obstruction - sepsis can cause "sepsis-associated cholestasis," an indirect systemic effect on the liver, elevating conjugated bilirubin. This is the most plausible clinical link if it exists.
2. Medication effects - some antibiotics used for urinary infections (e.g., trimethoprim/sulfamethoxazole) are noted in the Washington Manual as causing "cholestatic jaundice" and "obstructive uropathy" as two separate, unrelated side effects of the same drug - not one causing the other.
3. Coincidental liver/biliary disease - gallstones, hepatitis, or hemolysis occurring independently in the same patient.
4. Severe dehydration or multi-organ stress in advanced obstructive uropathy could stress the liver secondarily, but this is uncommon and nonspecific.

Bottom line